monkey

Anti-Mouse/Human/Rat/Monkey/Hamster/Canine/Bovine TGF-β Antibody (1D11.16.8) is an IgG antibody inhibitor targeting TGF-β in multiple species including mouse, human, rabbit, monkey, hamster, dog, and cow. For information on the isotype control, refer to Mouse IgG1 kappa, Isotype Control.

Anti-Mouse/Rat/Monkey/Human ICOS/CD278 Antibody (C398.4A) is an IgG antibody inhibitor derived from American hamster, targeting ICOS/CD278 in mice, rats, monkeys, and humans.

Anti-Monkey/Human MDR-1/CD243 Antibody (UIC2) is an IgG2a, κ monoclonal antibody derived from mice, designed to inhibit MDR-1/CD243 proteins in monkeys or humans.

Anti-Human/Monkey CD16a Antibody (3G8) is a monoclonal antibody targeting human and monkey CD16a and can be used in immunological research.

Anti-Human/Mouse/Monkey PD-1 Antibody (2E5) is a monoclonal antibody targeting human, mouse and monkey PD-1 and can be used in cancer immunotherapy research.

Anti-Human/Mouse/Monkey CXCR3 Antibody（9C5) is a monoclonal antibody targeting human, mouse and monkey CXCR3 and can be used in immunological research.

Anti-Human/Monkey/Canine IL-17A Antibody (Mab7) is a monoclonal antibody targeting human, monkey and canine IL-17A and can be used in inflammation research.

Anti-Human/Mouse/Rat/Monkey/Canine/Rabbit IL-1b Antibody (AB7) is a monoclonal antibody targeting human, mouse, rat, monkey, canine and rabbit IL-1β and can be used in inflammation research.

Anti-Human/Monkey NKG2D Antibody (16F16) is a monoclonal antibody targeting human and monkey NKG2D and can be used in cancer immunotherapy research.

Anti-Human/Monkey NKG2D Antibody (ON72) is a monoclonal antibody targeting human and monkey NKG2D and can be used in cancer immunotherapy research.

Anti-Human/Mouse/Monkey CLDN18.2 Antibody（25C7A5-HZ1） is a monoclonal antibody targeting human, mouse and monkey CLDN18.2 and can be used in cancer research.

Anti-Human/Mouse/Monkey TL1A Antibody（1D1） is a monoclonal antibody targeting human, mouse and monkey TL1A and can be used in inflammation research.

Anti-Human/Monkey CD28 Antibody (2D8.S) is a monoclonal antibody targeting human and monkey CD28. It can be used for T-cell costimulation research.

Anti-Monkey/Human CD40L/CD154 Antibody (5C8) is an IgG2a inhibitor derived from mice that targets CD40L/CD154 in monkeys and humans.

Anti-Monkey/Human MHC class II (HLA-DR) Antibody (L243) is an IgG2a, κ antibody inhibitor derived from mice that targets monkey or human MHC class II.

Anti-Monkey/Human CD28 Antibody (CD28.2) is a mouse-derived inhibitory antibody targeting monkey/human CD28.Anti-Monkey/Human CD28 Antibody (CD28.2) blocks CD28 signaling and is suitable for immunological research.

Anti-Monkey/Human CD20 Antibody (2H7) is a mouse-derived antibody that specifically targets the CD20 antigen in monkeys and humans and exerts an inhibitory effect. It achieves selective depletion of B cells through its targeting action and is commonly used in research on inflammatory and metabolic diseases such as diabetes and experimental autoimmune encephalomyelitis (EAE).

Guselkumab (CNTO 1959) is a recombinant human IgG1 monoclonal antibody targeting the IL-23p19 subunit. Guselkumab binds to human cynomolgus monkey IL-23 with Kd values of 3.3 and 1.9 pmol/L, respectively. Guselkumab can inhibit the production of cytokines downstream of IL-23 signaling pathway, and can be used in the study of psoriatic arthritis.

Rozanolixizumab (RYSTIGGO) is a high-affinity humanized immunoglobulin G4 monoclonal antibody targeting Fc receptors (FcRn) in human newborns for the study of pathogenic IgG in autoimmune and alloimmune diseases.

Alomfilimab (KY-1044) is a humanized monoclonal antibody targeting the inducible co-stimulator receptor (ICOS). As a selective ICOS blockade, it manipulates ICOS expression heterogeneity on T-cell subtypes. It can be used to study tumors.

Ezabenlimab (BI-754091) is a humanized monoclonal antibody targeting programmed cell death protein-1 with antitumor activity that blocks the interaction of PD-1 with PD-L1 and PD-L2, inhibits tumor growth in vivo, and can be used to study advanced solid tumors.

Etrolizumab (rhuMAb Beta7) is a humanized intestinal-selective anti-β7 integrin monoclonal antibody that selectively blocks the transport and retention of lymphocytes in the intestinal tract for the study of inflammatory bowel disease (IBD).

Simlukafusp alfa (FAP-IL2v) is a tumor-targeting immune cytokine, a human IgG1 antibody, with antitumor activity and immunostimulatory properties that potentiate in vitro and in vivo activity of therapeutic antibodies mediating antibody-dependent or T-cell-independent cytotoxicity (TDCC) and programmed death ligand 1 (PD-L1) checkpoint inhibition.

Canakinumab (ACZ885) is a recombinant human IL-1β-targeting monoclonal antibody that inhibits human and chorioallantoic monkey IL-1β with IC50 values of 43.6 and 40.8 pM, respectively. It exhibits anti-inflammatory activity by neutralizing IL-1β signaling, and it has been used for the treatment of gout and coronary artery disease.